US7977493B2 - Chemiluminescent reagents - Google Patents
Chemiluminescent reagents Download PDFInfo
- Publication number
- US7977493B2 US7977493B2 US11/494,991 US49499106A US7977493B2 US 7977493 B2 US7977493 B2 US 7977493B2 US 49499106 A US49499106 A US 49499106A US 7977493 B2 US7977493 B2 US 7977493B2
- Authority
- US
- United States
- Prior art keywords
- solution
- chemiluminescent
- chemiluminescent reagent
- mmol
- test tube
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related, expires
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims description 67
- 238000007710 freezing Methods 0.000 claims abstract description 7
- 230000008014 freezing Effects 0.000 claims abstract description 7
- 239000000243 solution Substances 0.000 claims description 93
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 33
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 31
- 239000007997 Tricine buffer Substances 0.000 claims description 19
- 239000007864 aqueous solution Substances 0.000 claims 4
- 239000000463 material Substances 0.000 claims 2
- 239000013076 target substance Substances 0.000 claims 2
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 abstract description 17
- 239000000126 substance Substances 0.000 abstract description 14
- 150000001923 cyclic compounds Chemical class 0.000 abstract description 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract description 8
- 238000001514 detection method Methods 0.000 abstract description 7
- 238000005259 measurement Methods 0.000 abstract description 7
- 238000011002 quantification Methods 0.000 abstract description 6
- 239000012535 impurity Substances 0.000 abstract description 4
- 238000010348 incorporation Methods 0.000 abstract description 4
- 230000035945 sensitivity Effects 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 description 39
- 102000003992 Peroxidases Human genes 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 10
- 238000004401 flow injection analysis Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000000872 buffer Substances 0.000 description 8
- 238000010979 pH adjustment Methods 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 7
- XLSZMDLNRCVEIJ-UHFFFAOYSA-N 4-methylimidazole Chemical compound CC1=CNC=N1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 description 6
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 6
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 6
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 6
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 5
- 229930024421 Adenine Natural products 0.000 description 5
- 229960000643 adenine Drugs 0.000 description 5
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 4
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 4
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- AXJZCJSXNZZMDU-UHFFFAOYSA-N (5-methyl-1h-imidazol-4-yl)methanol Chemical compound CC=1N=CNC=1CO AXJZCJSXNZZMDU-UHFFFAOYSA-N 0.000 description 3
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 3
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 3
- VYDWQPKRHOGLPA-UHFFFAOYSA-N 5-nitroimidazole Chemical compound [O-][N+](=O)C1=CN=CN1 VYDWQPKRHOGLPA-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 3
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 3
- 229930010555 Inosine Natural products 0.000 description 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 3
- 229960005305 adenosine Drugs 0.000 description 3
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 3
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 3
- 229960003459 allopurinol Drugs 0.000 description 3
- 229960001948 caffeine Drugs 0.000 description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940095074 cyclic amp Drugs 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 description 3
- 229960003786 inosine Drugs 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 3
- 150000003212 purines Chemical class 0.000 description 3
- 229940075420 xanthine Drugs 0.000 description 3
- RNIPJYFZGXJSDD-UHFFFAOYSA-N 2,4,5-triphenyl-1h-imidazole Chemical compound C1=CC=CC=C1C1=NC(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)N1 RNIPJYFZGXJSDD-UHFFFAOYSA-N 0.000 description 2
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 108700020962 Peroxidase Proteins 0.000 description 2
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- KNJDBYZZKAZQNG-UHFFFAOYSA-N lucigenin Chemical compound [O-][N+]([O-])=O.[O-][N+]([O-])=O.C12=CC=CC=C2[N+](C)=C(C=CC=C2)C2=C1C1=C(C=CC=C2)C2=[N+](C)C2=CC=CC=C12 KNJDBYZZKAZQNG-UHFFFAOYSA-N 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- -1 alantoin Chemical compound 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Definitions
- the present invention relates to novel chemiluminescent reagents for use in the detection and quantification of various substances, for example, in clinical applications.
- chemiluminescence measurements are suitable for clinical tests in terms of their simple availability, promptness and high sensitivity.
- Enzymes used for the chemiluminescence measurements are peroxidases, alkaline phosphotases, glycol oxidases, and the like.
- Suitable chemiluminescent substances used for the chemiluminescence measurements are luminol, isoluminol, lophine, lucigenin, peryoxalate, and the like. See, the following Patent Publication Nos. 1 to 6.
- chemiluminescent substances have the disadvantages of relatively poor solubility in water, which is essential for chemiluminescent detection, incorporation of impurities, and possible degradation during storage.
- luminol and peryoxalate are required to be dissolved in organic solvents, such as acetonitrile, for the preparation of high-concentration solutions.
- Lucigenin has the problems of short luminescence retention and severe background noise.
- Lophine chemiluminescence has the problems of poor water solubility and low luminescence yield.
- the present invention has been made in view of the above problems of the conventional chemiluminescent substances used for chemiluminescence measurements, and it is an object of the present invention to provide novel chemiluminescent substances that have a sensitivity comparable to that of luminol chemiluminescence, are highly water-soluble, have no incorporation of impurities, are not degraded during storage, have high reproducibility in measurement results, and are very suitable for use in the detection and quantification of various substances in many applications, e.g., clinical applications.
- a chemiluminescent reagent which is prepared by freezing a solution of a peroxidized nitrogen-containing five-membered cyclic compound.
- a chemiluminescent reagent which is prepared by lyophilizing a solution of a peroxidized nitrogen-containing five-membered cyclic compound.
- the nitrogen-containing five-membered cyclic compound is selected from pyrrole, imidazole, and purine compounds.
- the chemiluminescent reagents of the present invention are prepared by freezing or lyophilizing a solution of a peroxidized nitrogen-containing five-membered cyclic compound. Specifically, the chemiluminescent reagents of the present invention are prepared by reacting a solution a nitrogen-containing five-membered cyclic compound, an aqueous hydrogen peroxide solution and an alkaline buffer, and freezing or lyophilizing the reaction solution.
- the chemiluminescent reagents of the present invention are prepared by introducing a solution of a nitrogen-containing five-membered cyclic compound, an aqueous hydrogen peroxide solution and an alkaline buffer into a test tube, reacting the mixture under heating to about 40° C. to about 60° C. for about 30 minutes, and directly freezing or lyophilizing the test tube.
- Storage stability of the chemiluminescent reagents of the present invention could be achieved by simply freezing or lyophilization of the reaction solution or a fraction obtained by high-performance liquid chromatography of the reaction solution.
- the frozen chemiluminescent reagent of the present invention is allowed to thaw at room temperature and is then used for the detection and quantification of various substances.
- the lyophilized chemiluminescent reagent of the present invention is dissolved in distilled water in the same volume removed by the lyophilization, and is then used for the detection and quantification of various substances.
- the nitrogen-containing five-membered cyclic compound used to prepare the chemiluminescent reagents according to the present invention is selected from pyrrole, imidazole, and purine compounds.
- suitable pyrrole compounds include, but are not limited to, pyrrole, proline, and porphyrin.
- suitable imidazole compounds include, but are not limited to, imidazole, 2-methylimidazole, 4-methylimidazole, 4-methyl-5-hydroxymethylimidazole, benzimidazole, 4-nitroimidazole, alantoin, ethylene urea, histidine, and pyrazole.
- purine compounds include, but are not limited to, theophylline, caffeine, xanthine, allopurinol, inosine, tryptophan, adenine, adenosine, nicotine amide adenine dinucleotide (NAD), reduced nicotine amide adenine dinucleotide (NADH), adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP), cyclic AMP, serotonin, and aciclovir.
- theophylline caffeine, xanthine, allopurinol, inosine, tryptophan
- adenine, adenosine nicotine amide adenine dinucleotide (NAD), reduced nicotine amide adenine dinucleotide (NADH), adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine mono
- Non-limiting examples of suitable alkaline buffers that can be used to prepare the chemiluminescent reagents of the present invention include Tricine buffers, Tris hydrochloride buffers, and borate buffers.
- the concentration of the alkaline buffer used is dependent on the kind of the buffer.
- a Tricine buffer (pH 9.4) having a concentration of 50 mmol/L is used in the present invention.
- the aqueous hydrogen peroxide solution used to prepare the chemiluminescent reagents of the present invention preferably has a concentration of about 100 mmol/L.
- the chemiluminescent reagent After the test tube containing the chemiluminescent reagent thus prepared was taken out of the freezer, the chemiluminescent reagent was thawed at room temperature to obtain a solution. 50 ⁇ l of the solution was injected into a flow cell filled with an immobilized peroxidase enzyme using a flow injection system. As a result, it could be confirmed that the chemiluminescent reagent showed a chemiluminescence intensity comparable to that of luminol chemiluminescence.
- the chemiluminescent reagent After the test tube containing the chemiluminescent reagent thus prepared was taken out of the freezer, the chemiluminescent reagent was thawed at room temperature to obtain a solution. 50 ⁇ l of the solution was injected into a flow cell filled with an immobilized peroxidase enzyme using a flow injection system. As a result, it could be confirmed that the chemiluminescent reagent showed a chemiluminescence intensity comparable to that of luminol chemiluminescence.
- the chemiluminescent reagent After the test tube containing the chemiluminescent reagent thus prepared was taken out of the freezer, the chemiluminescent reagent was thawed at room temperature to obtain a solution. 50 ⁇ l of the solution was injected into a flow all filled with an immobilized peroxidase enzyme using a flow injection system. As a result, it could be confirmed that the chemiluminescent reagent showed a chemiluminescence intensity comparable to that of luminol chemiluminescence.
- each chemiluminescent reagent thus prepared was taken out of the freezer, the chemiluminescent reagent was thawed at room temperature to obtain a solution. 50 ⁇ l of the solution was injected into a flow cell filled with an immobilized peroxidase enzyme using a flow injection system. As a result, it could be confirmed that all the chemiluminescent reagents showed a chemiluminescence intensity comparable to that of luminol chemiluminescence.
- the chemiluminescent reagent After the test tube containing the chemiluminescent reagent thus prepared was taken out of the freezer, the chemiluminescent reagent was thawed at room temperature to obtain a solution. 50 ⁇ l of the solution was injected into a flow cell filled with an immobilized peroxidase enzyme using a flow infection system. As a result, it could be confirmed that the chemiluminescent reagent showed a chemiluminescence intensity comparable to that of luminol chemiluminescence.
- each chemiluminescent reagent thus prepared was taken out of the freezer, the chemiluminescent reagent was thawed at room temperature to obtain a solution. 50 ⁇ l of the solution was injected into a flow cell filled with an immobilized peroxidase enzyme using a flow injection system. As a result, it could be confirmed that all the chemiluminescent reagents showed a chemiluminescence intensity comparable to that of luminol chemiluminescence.
- chemiluminescent reagent showed a chemiluminescence intensity comparable to that of luminol chemiluminescence.
- chemiluminescent reagent showed a chemiluminescence intensity comparable to that of luminol chemiluminescence.
- chemiluminescent reagent showed a chemiluminescence intensity comparable to that of luminol chemiluminescence.
- chemiluminescent reagent showed a chemiluminescence intensity comparable to that of luminol chemiluminescence.
- the chemiluminescent substances of the present invention have a sensitivity comparable to that of luminol chemiluminescence, are highly water soluble, have no incorporation of impurities, are not degraded during storage, emit light by direct oxidation, have high reproducibility in measurement results, and are very suitable for use in the detection and quantification of various substances in many applications, e.g., clinical applications.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
- (Patent Publication No. 1) Japanese Patent Application Laid-Open No. Sho 59-171839
- (Patent Publication No. 2) Japanese Patent Application Laid-Open No. Hei 2-174694
- (Patent Publication No. 3) Japanese Patent Application Laid-Open No. Hei 2-291299
- (Patent Publication No. 4) Japanese Patent Application Laid-Open No. Hei 3-35147
- (Patent Publication No. 5) Japanese Patent Application Laid-Open No. Hei 7-327694
- (Patent Publication No. 6) Japanese Patent Application Laid-Open No. Hei 8-313443
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/494,991 US7977493B2 (en) | 2006-07-28 | 2006-07-28 | Chemiluminescent reagents |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/494,991 US7977493B2 (en) | 2006-07-28 | 2006-07-28 | Chemiluminescent reagents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| US20080027222A1 US20080027222A1 (en) | 2008-01-31 |
| US7977493B2 true US7977493B2 (en) | 2011-07-12 |
Family
ID=38987190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/494,991 Expired - Fee Related US7977493B2 (en) | 2006-07-28 | 2006-07-28 | Chemiluminescent reagents |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US7977493B2 (en) |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59171839A (en) | 1983-02-11 | 1984-09-28 | ナシヤナル、リサ−チ、デイヴエラツプマント、コ−パレイシヤン | Sensitized luminescence test method |
| US4598044A (en) | 1983-02-11 | 1986-07-01 | National Research Development Corporation | Enhanced luminescent or luminometric assay |
| US4645646A (en) * | 1983-07-29 | 1987-02-24 | Henning Berlin Gmbh Chemie-Und Pharmawerk | Luminescence immunoassay for haptens and chemiluminescence labelled hapten conjugates |
| US4835101A (en) * | 1986-02-10 | 1989-05-30 | Kallestad Diagnostics, Inc. | Luminescent analyses with enhanced storage stability |
| JPH02174694A (en) | 1988-09-30 | 1990-07-06 | Fujirebio Inc | Chemiluminescent assay for peroxidase activity |
| JPH02291299A (en) | 1989-02-14 | 1990-12-03 | Takeda Chem Ind Ltd | Method for enhancing chemiluminescence |
| JPH0335147A (en) | 1989-07-03 | 1991-02-15 | Doujin Kagaku Kenkyusho:Kk | Detection of chemiluminescence |
| US5106732A (en) | 1989-02-14 | 1992-04-21 | Takeda Chemical Industries, Ltd. | Method for enhancement of chemiluminescence |
| JPH07327694A (en) | 1994-06-14 | 1995-12-19 | Hitachi Chem Co Ltd | Reagent for chemoluminescence measurement and measuring method therefor |
| JPH08313443A (en) | 1995-05-19 | 1996-11-29 | Kdk Corp | Modified chemiluminescence measuring method |
| US6565894B1 (en) * | 1999-11-05 | 2003-05-20 | Francis X. Smith | Healthcare formulations comprising imidazole and hydrogen peroxide |
-
2006
- 2006-07-28 US US11/494,991 patent/US7977493B2/en not_active Expired - Fee Related
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59171839A (en) | 1983-02-11 | 1984-09-28 | ナシヤナル、リサ−チ、デイヴエラツプマント、コ−パレイシヤン | Sensitized luminescence test method |
| US4598044A (en) | 1983-02-11 | 1986-07-01 | National Research Development Corporation | Enhanced luminescent or luminometric assay |
| US4645646A (en) * | 1983-07-29 | 1987-02-24 | Henning Berlin Gmbh Chemie-Und Pharmawerk | Luminescence immunoassay for haptens and chemiluminescence labelled hapten conjugates |
| US4835101A (en) * | 1986-02-10 | 1989-05-30 | Kallestad Diagnostics, Inc. | Luminescent analyses with enhanced storage stability |
| JPH02174694A (en) | 1988-09-30 | 1990-07-06 | Fujirebio Inc | Chemiluminescent assay for peroxidase activity |
| JPH02291299A (en) | 1989-02-14 | 1990-12-03 | Takeda Chem Ind Ltd | Method for enhancing chemiluminescence |
| US5106732A (en) | 1989-02-14 | 1992-04-21 | Takeda Chemical Industries, Ltd. | Method for enhancement of chemiluminescence |
| JPH0335147A (en) | 1989-07-03 | 1991-02-15 | Doujin Kagaku Kenkyusho:Kk | Detection of chemiluminescence |
| JPH07327694A (en) | 1994-06-14 | 1995-12-19 | Hitachi Chem Co Ltd | Reagent for chemoluminescence measurement and measuring method therefor |
| JPH08313443A (en) | 1995-05-19 | 1996-11-29 | Kdk Corp | Modified chemiluminescence measuring method |
| US6565894B1 (en) * | 1999-11-05 | 2003-05-20 | Francis X. Smith | Healthcare formulations comprising imidazole and hydrogen peroxide |
Non-Patent Citations (1)
| Title |
|---|
| Hadd et al. "Stopped-Flow Kinetics Investigation of the Imidazole-Catalyzed Peroxyoxalate Chemiluminescenece Reaction" J. Org. Chem. 1998, vol. 63, pp. 3023-3031. * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20080027222A1 (en) | 2008-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101396691B1 (en) | Use of ammonium and phosphate ions for improving the detection of luciferase | |
| US20070190589A1 (en) | Enzymatic fluorometric assay for cAMP and adenylate cyclase | |
| CN105181970A (en) | Stable kit for detecting homocysteine | |
| FI69641B (en) | OVER REAGENTS FOR THE CONSTRUCTION OF CREATIVES | |
| JPH09511581A (en) | Chemical assay calibration method | |
| CN106868096B (en) | High-stability and low-cost glucose detection reagent by hexokinase method | |
| US20130203068A1 (en) | Dual-acceptor time-resolved-fret | |
| KR20250028294A (en) | Phasing and prephasing correction of base calling in next-generation sequencing | |
| US7977493B2 (en) | Chemiluminescent reagents | |
| US7718389B2 (en) | Stabilizing composition and stabilizing method of coelenterazine solution for high-throughput measurement of luciferase activity | |
| JP4591820B2 (en) | Chemiluminescent reagent | |
| CN101514984B (en) | Reagent for determining serum free carnitine | |
| CN108884030B (en) | Improved labeling of nucleophiles using bipyridines | |
| US10799603B2 (en) | Kinase and/or phosphatase sensing via hydroxyquinoline-sensitized chelates | |
| SU1041568A1 (en) | Reagent for detecting adenosine-5-triphosphate | |
| US5972635A (en) | Sulfonic acid group buffered dry analytical element for quantitative analysis of creatine kinase or its MB isozyme | |
| RU2164241C2 (en) | Reagent for adenosine 5'-triphosphate assay | |
| JP3992467B2 (en) | Method for simultaneous preparation of sample capable of measuring cAMP and cGMP with high sensitivity | |
| JP2000166550A (en) | Stabilization of bioluminescent reagent | |
| Hammler | Synthesis and Characterization of Dye-Labeled Nucleotides to Follow Protein Activity | |
| Davidsen | Tools to investigate aspartate limited proliferation of cancer cells | |
| US8871520B2 (en) | Uracil-specific fluorescence detection reaction and method for examining dihydropyrimidine dehydrogenase deficiency | |
| SU1495382A1 (en) | Method of determining the quantity of high-molecular alcohols in solution | |
| WO2021241446A1 (en) | Method for detecting target molecule in specimen, and target molecule detection kit | |
| Lindbrg et al. | Bioluminescent determination of ATP in ischemic rat heart |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: CHEMCO SCIENTIFIC CO., LTD., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NOZAKI, OSAMU;MUNESUE, MOTONORI;KAWAMOTO, HIROKO;REEL/FRAME:018259/0004 Effective date: 20060721 |
|
| AS | Assignment |
Owner name: NOZAKI, OSAMU, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHEMCO SCIENTIFIC CO., LTD.;REEL/FRAME:019803/0254 Effective date: 20070901 Owner name: MUNESUE, MOTONORI, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHEMCO SCIENTIFIC CO., LTD.;REEL/FRAME:019803/0254 Effective date: 20070901 Owner name: CHEMCO SCIENTIFIC CO., LTD., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHEMCO SCIENTIFIC CO., LTD.;REEL/FRAME:019803/0254 Effective date: 20070901 Owner name: KAWAMOTO, HIROKO, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHEMCO SCIENTIFIC CO., LTD.;REEL/FRAME:019803/0254 Effective date: 20070901 |
|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
| LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
| STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
| FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20190712 |